Mathias Uhlén’s protein atlas is recognised as a global resource

The Human Protein Atlas is the first database in Sweden to be designated a Global Core Biodata Resource. According to Mathias Uhlén, this is a quality hallmark ...

Vicore tar in 200 miljoner — utvecklar behandling mot lungfibros

Göteborgsbaserade Vicore Pharma, som utvecklar behandlingar för svåra lungsjukdomar, har tagit in 200 miljoner kronor via en riktad nyemission.

Double up for Korbinian Löbmann

This year, Korbinian Löbmann will moderate the New Updates in Drug Formulation & Bioavailability meeting in Copenhagen for the fifth time. Furthermore, he will ...

Here are the pharmaceutical companies best prepared for AI

How well prepared are pharmaceutical companies in the field of artificial intelligence? That is what a new analysis has tried to evaluate.

Xbrane tar in 350 miljoner för fortsatt utveckling och uppskalning

Solnabaserade biosimilarbolaget Xbrane Biopharma tar in totalt 350 miljoner kronor genom dels en riktad nyemission, dels en finansiering via konvertibla obligationer.

A growing industry in Denmark: “One new life science company a week”

The life science sector in eastern Denmark continues to grow in the number of employees, as well as the number of companies. An emerging problem is the shortage of labour, a new...

Study: Chat GPT is more empathetic than doctors

The AI tool Chat GPT is not only more accurate when it comes to answering patient questions – the chatbot is also perceived as almost 10 times more empathetic t...

Han tar över som ordförande i CTR

Bengt Dahlström, grundare av Center for Translational Research, har efter sju år som styrelseordförande i koncernen lämnat över ordförandeklubban till Hans Andreasson.

We will now publish more news in English – and offer yet another newsletter

Starting next week, Life Science Sweden will begin offering a newsletter entirely in English.

Small robots to deliver pharmaceuticals to the body

Robots that can operate inside the body and a platform that combines ultrasound with AI. These are a couple of the technologies that have qualified for a list t...

MVA:s CEO: “Our investments should improve people´s everyday lives”

Involuntary infertility and diabetes are two of the areas on the agenda of the Medicon Valley Alliance.

Egetis bekräftar budsamtal

Den svenska läkemedelsutvecklaren Egetis Therapeutics för diskussioner om ett potentiellt bud på bolaget. Det bekräftar företaget i en kommentar till ihärdiga r...

Egetis lägger ned buddiskussionerna

Svenska läkemedelsutvecklaren Egetis Therapeutics har gått ut med att diskussionerna om ett potentiellt förvärv av företaget nu har lagts ner.

The fast route to a safe insulin pen

the pens using the Festo automation platform.

The life science strategy – what the industry wants

The process of updating the national life science strategy has begun at the government’s life science office. According to industry stakeholders, Sweden’s compe...

Företag i Kanada får börja tillverka kokain

Ett företag i den kanadensiska provinsen British Columbia har fått tillstånd att tillverka och sälja kokain på licens.

Dansk-svensk mikrobiom-satsning lockade företag och talanger

Fem mikrobioföretag har etablerat sig och över 100 internationella talanger har anställts inom ramen för Microbiome Signature Project i Öresundsregionen. Alla u...

Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed

Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.

This is the future location of the new national innovation cluster

Mölndal and Goco Health Innovation City will be the site of a new national innovation cluster for advanced therapies. The business community and the Swedish gov...

New report: Fewer PhDs in life sciences

A new report from Vinnova suggests that competency returns in the life science sector are declining.

SLS Invest AB

Nipeg Invest AB

Swedish breakthrough in Alzheimer’s: “We can finally present great data”

Treatments for Alzheimer’s disease are currently among the hottest topics in drug development. Two Swedish research companies with high ambitions and successes ...

Så mycket väntas lecanemab sälja globalt

Försäljningen av Leqembi (lecanemab), som nyligen fick ett accelererat USA-godkännande som behandling mot Alzheimers sjukdom, väntas globalt uppgå till sju milj...